scispace - formally typeset
H

Henry Lowe

Researcher at University of Maryland, Baltimore

Publications -  26
Citations -  423

Henry Lowe is an academic researcher from University of Maryland, Baltimore. The author has contributed to research in topics: Hepatitis B & Tillandsia recurvata. The author has an hindex of 8, co-authored 25 publications receiving 264 citations.

Papers
More filters
Journal ArticleDOI

Potential of Flavonoid-Inspired Phytomedicines against COVID-19.

TL;DR: In silico studies show that these flavonoid-based molecules can bind with high affinity to the spike protein, helicase, and protease sites on the ACE2 receptor used by the severe acute respiratory syndrome coronavirus 2 to infect cells and cause COVID-19.
Journal ArticleDOI

The Endocannabinoid System: A Potential Target for the Treatment of Various Diseases

TL;DR: In this article, the potential of the ECS in the treatment of various diseases, and the suggestion that many of these secondary metabolites of Cannabis sativa L. (hereafter referred to as “medical cannabis”), may also have potential as lead compounds in the development of cannabinoid-based pharmaceuticals for a variety of diseases.
Journal ArticleDOI

Relationship between Processing Method and the Glycemic Indices of Ten Sweet Potato (Ipomoea batatas) Cultivars Commonly Consumed in Jamaica

TL;DR: It is indicated that consumption of boiled sweet potatoes could minimize postprandial blood glucose spikes and therefore, may prove to be more efficacious in the management of type 2 diabetes mellitus.
Journal ArticleDOI

Potential of cannabidiol for the treatment of viral hepatitis

TL;DR: Preliminary screening of cannabidiol (CBD) revealed that CBD is active againstHCV but not against HBV in vitro, suggesting that CBD could be further developed and used therapeutically against HCV.
Journal ArticleDOI

Flavonoid Derivative of Cannabis Demonstrates Therapeutic Potential in Preclinical Models of Metastatic Pancreatic Cancer.

TL;DR: In vivo results demonstrate therapeutic efficacy in delaying both local and metastatic tumor progression in animal models with pancreatic cancer when using FBL-03G sustainably delivered from smart radiotherapy biomaterials, providing impetus for further studies toward clinical translation.